Globus Medical (NYSE:GMED) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Globus Medical (NYSE:GMED) released its quarterly earnings data on Thursday. The medical device company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.03, FiscalAI reports. Globus Medical had a return on equity of 14.51% and a net margin of 17.76%. The business had revenue of $763.72 million for the quarter, compared to analysts’ expectations of $792.39 million. During the same period in the prior year, the firm posted $1.18 EPS. The firm’s quarterly revenue was down .7% on a year-over-year basis. Globus Medical updated its FY 2026 guidance to 4.950-5.050 EPS.

Here are the key takeaways from Globus Medical’s conference call:

• Q3 revenue declined 0.7% to $763.7 million, as 3% growth in the base business excluding Nevro was offset by Nevro’s 25.7% decline. U.S. Spine grew 2%, held back by delayed product launches and lower-than-expected contributions from competitive recruiting.
• Globus lowered its 2026 revenue outlook to $3.09 billion from $3.18 billion–$3.22 billion, citing Nevro weakness and limited contribution from new products this year. It reiterated non-GAAP EPS guidance of $4.95–$5.05.
• Profitability and cash generation improved despite the revenue decline: non-GAAP EPS rose 4% to $1.23, adjusted gross margin expanded 140 basis points to 69.5%, and free cash flow reached a record $225 million.
• Management expects new spine products—including SCRIPT, XLIF Prone, and eIQ—and greater robot and navigation pull-through to support growth in 2027 and beyond. Enabling Technologies revenue grew 24% in Q3, while deployed units rose 45% year over year.
• The board authorized an additional $500 million share-repurchase program; Globus repurchased $142.9 million of shares in Q3. Management also expects continued margin improvement, while noting that higher R&D investment is planned.

Globus Medical Trading Down 13.2%

NYSE:GMED traded down $10.77 during trading hours on Friday, reaching $70.67. The company had a trading volume of 9,272,194 shares, compared to its average volume of 1,418,585. Globus Medical has a 52 week low of $70.39 and a 52 week high of $101.40. The firm has a market cap of $9.49 billion, a price-to-earnings ratio of 14.30, a PEG ratio of 1.14 and a beta of 0.98. The firm’s 50 day moving average price is $77.20 and its 200-day moving average price is $83.18.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Analyst Ratings Changes

Several research firms have recently weighed in on GMED. Canaccord Genuity Group decreased their price target on Globus Medical from $115.00 to $105.00 and set a “buy” rating for the company in a research note on Friday. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. UBS Group assumed coverage on Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price objective for the company. Truist Financial decreased their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Finally, BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $96.92.

Insider Buying and Selling at Globus Medical

In other news, Director James R. Tobin sold 30,000 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the transaction, the director directly owned 15,000 shares of the company’s stock, valued at $1,118,700. This represents a 66.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Stephen Zarrilli sold 25,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the transaction, the director owned 25,000 shares in the company, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 60,000 shares of company stock worth $4,838,400. Insiders own 18.38% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.